What is Pleural Effusion?
Pleural effusion is an excessive accumulation of fluid in the pleural space between the visceral and parietal pleura, preventing full lung expansion during inspiration and causing dyspnea, pleuritic chest pain, and occasionally dry cough 1.
Etiology
Non-malignant pleural effusions account for approximately 75% of all pleural effusions, with an incidence of 252 per 100,000 population, far exceeding malignant causes 2. The major etiologies include:
Most Common Causes:
- Congestive heart failure (most common overall)
- Pneumonia/parapneumonic effusions
- Malignancy (lung cancer most common, followed by breast cancer)
- Pulmonary embolism
- Cirrhosis/hepatic hydrothorax
- End-stage renal failure 3
Other Important Causes:
- Tuberculosis (especially in endemic areas)
- Post-cardiac surgery
- Trauma (with rib fractures, hemothorax)
- Rheumatoid arthritis and other inflammatory conditions
- Benign asbestos-related pleural effusion
- Dressler syndrome
- Nonspecific pleuritis 2, 3
Critical caveat: The term "benign" is misleading—non-malignant effusions carry 1-year mortality rates of 50% in heart failure, 46% in renal failure, and 25% in liver failure, often matching or exceeding malignant effusion mortality 2.
Signs and Symptoms
Primary Symptoms:
- Dyspnea (initially on exertion, progressing to rest)
- Pleuritic chest pain
- Dry cough (predominantly)
- Reduced exercise tolerance 1, 4
Physical Examination Findings:
- Decreased breath sounds over the affected area
- Dullness to percussion
- Decreased tactile fremitus
- Asymmetric chest expansion
Management
Step 1: Initial Diagnostic Approach
Perform thoracentesis for all new and unexplained pleural effusions using ultrasound guidance 5, 6. Image-guided thoracentesis reduces pneumothorax risk and increases successful fluid sampling (92.3% vs 78.2% success rate) compared to non-image-guided approaches 5.
Step 2: Classify as Transudate vs Exudate
Laboratory analysis distinguishes transudates (treat underlying condition) from exudates (requires further investigation) 3, 1:
Transudate Causes:
- Heart failure (look for cardiomegaly, bilateral effusions, pericardial effusion)
- Cirrhosis (look for signs of liver disease)
- Nephrotic syndrome
Exudate Causes:
- Infection, malignancy, pulmonary embolism, inflammatory conditions
Step 3: CT Imaging for Exudates
CT features help narrow differential diagnosis 5:
Infection (Parapneumonic/Empyema/TB):
- Lentiform (lens-shaped) fluid configuration
- Visceral pleural thickening ("split pleura sign")
- Extrapleural fat hypertrophy (>2 mm) with increased density
- Adjacent pulmonary consolidation
Malignancy:
- Circumferential pleural thickening >1 cm
- Mediastinal pleural involvement
- Nodularity
- Chest wall invasion (unlike TB)
TB-Specific Features:
- Highly complex effusions with internal septations on ultrasound
- Circumferential thickening WITHOUT chest wall invasion
- Lymphocyte-rich fluid with complex septations predicts TB 5
Important pitfall: Malignancy and infection coexist in approximately 5% of cases—follow up imaging for up to 2 years if clinically concerning features persist 5.
Step 4: Additional Testing Based on Suspected Etiology
- Natriuretic peptides for heart failure
- Adenosine deaminase for tuberculosis
- Cytology for malignancy (may require multiple samples)
- Pleural biopsy if diagnosis remains unclear after thoracentesis 7
For undiagnosed effusions after initial thoracentesis: Perform pleuroscopic biopsies, but attempt image-guided biopsies first if pleural nodularity or thickening is present 7.
Step 5: Definitive Management
For Transudative Effusions:
Treat the underlying medical disorder (heart failure optimization, diuretics, renal replacement therapy, liver transplant evaluation) 1.
For Large, Refractory Effusions (Transudate or Exudate):
Drain to provide symptomatic relief regardless of etiology 1.
For Parapneumonic Effusions/Empyema:
Treat with appropriate antibiotics PLUS intercostal drainage. Surgery may be needed if drainage fails or for bronchopleural fistula closure 1.
For Malignant Pleural Effusion:
Early definitive management is critical—only 39% of eligible patients currently receive guideline-consistent care 8.
For rapidly recurrent symptomatic MPE (recurrence within 14 days), immediately proceed to definitive management rather than repeat thoracentesis 8, 9:
- Talc pleurodesis (via chest tube or VATS) if lung is expandable and patient can tolerate inpatient procedure
- Indwelling pleural catheter (IPC) for trapped lung, poor performance status (high ECOG), or patient preference for ambulatory management
- Both have similar efficacy for symptom control and quality of life 9
Evidence supporting early definitive management: Patients receiving early intervention have fewer total pleural procedures (2.08 vs 3.51), fewer ED visits (0.23 vs 1.31 per patient), fewer hospitalizations (0.23 vs 0.99 per patient), and substantially lower costs ($9,857 vs $39,497 per patient) compared to repeated thoracentesis 8.
For Tuberculosis:
Pleural biopsy is recommended for diagnosis. Percutaneous closed pleural biopsy is easiest, least expensive, with minimal complications 1.
Key Technical Points:
- Use small-bore catheters for most non-traumatic conditions
- Avoid trocar insertion (increases complication risk)
- Routine ultrasound guidance is mandatory 10
Critical Clinical Pitfalls
Delaying definitive management in malignant effusions: 61% of patients with rapidly recurrent MPE undergo repeat thoracentesis instead of definitive therapy, leading to increased healthcare utilization and costs 8.
Missing coexistent malignancy in infection: Always consider follow-up imaging for up to 2 years if symptoms persist 5.
Assuming "benign" means good prognosis: Non-malignant effusions carry mortality rates comparable to or exceeding malignant effusions 2.
Performing thoracentesis without ultrasound guidance: This increases pneumothorax risk and reduces successful fluid sampling 5.
Failing to recognize trapped lung: This requires IPC rather than pleurodesis 9.